Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice

Atherosclerosis

Volumn 243, Issue 2, 2015, Pages 438-448

  Lu, Junyan ^a   Xiang, Guangda ^a   Liu, Min ^a   Mei, Wen ^a   Xiang, Lin ^a   Dong, Jing ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

AMPK; Atherosclerosis; Diabetes mellitus; Endothelium; Irisin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IRISIN; PROTEIN KINASE B; APOLIPOPROTEIN E; CYTOKINE; FIBRONECTIN; NOS3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROTIC PLAQUE; C57BL MOUSE; CELL CULTURE; CELL PROTECTION; DEFICIENCY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASODILATATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; CELLS, CULTURED; CYTOKINES; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBRONECTINS; GENETIC PREDISPOSITION TO DISEASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHENOTYPE; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFECTION; VASODILATION;

EID: 84946038245     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.10.020     Document Type: Article

References (42)

1. Booth G.L., Kapral M.K., Fung K., Tu J.V. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care 2006, 29:32-37.
2. Preis S.R., Hwang S.-J., Coady S., Pencina M.J., D'Agostino R.B., Savage P.J., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
3. Verma S., Buchanan M.R., Anderson T.J. Endothelial function testing as a biomarker of vascular disease. Circulation 2003, 108:2054-2059.
4. Kuhlencordt P.J., Gyurko R., Han E., Scherrer-Crosbie M., Aretz T.H., Hajjar R., et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001, 104:448-454.
5. Knowles J.W., Reddick R.L., Jennette J.C., Shesely E.G., Smithies O., Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J. Clin. Invest. 2000, 105:451-458.
6. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A., et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 1995, 96:60-68.
7. Boström P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481:463-468.
8. Liu J-J., Wong M.D.S., Toy W.C., Tan C.S., Liu S., Ng X.W., et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J. Diabetes Complicat. 2013, 27:365-369.
9. Choi Y-K., Kim M-K., Bae K.H., Seo H.A., Jeong J.Y., Lee W.K., et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res. Clin. Pract. 2013, 100:96-101.
10. Alis R., Sanchis-Gomar F., Pareja-Galeano H., Hernández-Mijares A., Romagnoli M., Víctor V.M., et al. Association between irisin and homocysteine in euglycemic and diabetic subjects. Clin. Biochem. 2014, 47:333-335.
11. Wang H.-H., Zhang X-W., Chen W., Huang Q.-X., Chen Q.-Q. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. J. Diabetes Complicat. 2015, 29:384-389.
12. Xiang L., Xiang G., Yue L., Zhang J., Zhao L. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis 2014, 235:328-333.
13. Hou N., Han F., Sun X. The relationship between circulating irisin levels and endothelial function in lean and obese subjects. Clin. Endocrinol. (Oxf.) 2015, 83:339-343.
14. Song H., Wu F., Zhang Y., Zhang Y., Wang F., Jiang M., et al. Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS One 2014, 9:e110273.
15. Boo Y.C., Sorescu G., Boyd N., Shiojima I., Walsh K., Du J., et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J. Biol. Chem. 2002, 277:3388-3396.
16. Michell B.J., Chen Z.P., Tiganis T., Stapleton D., Katsis F., Power D.A., et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 2001, 276:17625-17628.
17. Birck M.M., Saraste A., Hyttel P., Odermarsky M., Liuba P., Saukko P., et al. Endothelial cell death and intimal foam cell accumulation in the coronary artery of infected hypercholesterolemic minipigs. J. Cardiovasc. Transl. Res. 2013, 6:579-587.
18. Lindstedt K.A., Leskinen M.J., Kovanen P.T. Proteolysis of the pericellular matrix: a novel element determining cell survival and death in the pathogenesis of plaque erosion and rupture. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1350-1358.
19. Kockx M.M. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1519-1522.
20. García-Prieto C.F., Pulido-Olmo H., Ruiz-Hurtado G., Gil-Ortega M., Aranguez I., Rubio M.A., et al. Mild caloric restriction reduces blood pressure and activates endothelial AMPK-PI3K-Akt-eNOS pathway in obese Zucker rats. Vasc. Pharmacol. 2014, 65-66:3-12.
21. García-Prieto C.F., Hernández-Nuño F., Rio D.Del, Ruiz-Hurtado G., Aránguez I., Ruiz-Gayo M., et al. High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. Mol. Nutr. Food Res. 2015, 59:520-532.
22. Liu M., Xiang G., Lu J., Xiang L., Dong J., Mei W. TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling. Atherosclerosis 2014, 237:718-724.
23. Xiang G., Pu J., Yue L., Hou J., Sun H. Apha-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. Metabolism 2011, 60:480-485.
24. Williams K.J., Tabas I. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:1928.
25. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
26. Lerman A., Zeiher A.M. Endothelial function: cardiac events. Circulation 2005, 111:363-368.
27. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(23 Suppl. 1):III27-32.
28. Hambrecht R., Wolf A., Gielen S., Linke A., Hofer J., Erbs S., et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N. Engl. J. Med. 2000, 342:454-460.
29. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 1995, 332:481-487.
30. Prasad A., Tupas-Habib T., Schenke W.H., Mincemoyer R., Panza J.A., Waclawin M.A., et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000, 101:2349-2354.
31. Arcaro G., Cretti A., Balzano S., Lechi A., Muggeo M., Bonora E., et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002, 105:576-582.
32. Lteif A.A., Han K., Mather K.J. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005, 112:32-38.
33. Bell D.S., ÓKeefe J.H. Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance. J. Am. Coll. Cardiol. 2011, 58:778.
34. Mulvihill E.E., Assini J.M., Lee J.K., Allister E.M., Sutherland B.G., Koppes J.B., et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes 2011, 60:1446-1457.
35. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52:2795-2804.
36. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
37. Ho F.M., Lin W.W., Chen B.C., Chao C.M., Yang C.R., Lin L.Y., et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006, 18:391-399.
38. Santulli G., Pagano G., Sardu C., Xie W., Reiken S., D'Ascia S.L., et al. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J. Clin. Invest. 2015, 125:1968-1978.
39. Yuan Q., Chen Z., Santulli G., Gu L., Yang Z.G., Yuan Z.Q., et al. Functional role of Calstabin2 in age-related cardiac alterations. Nat. Sci. Rep. 2014, 4:7425.
40. Santulli G., Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics 2013, 14:1517-1526.
41. Santulli G., Trimarco B., Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. High Blood Press. Cardiovasc. Prev. 2013, 20:5-12.
42. Santulli G., Cipolletta E., Sorriento D., Del Giudice C., Anastasio A., Monaco S., et al. CaMK4 gene deletion induces hypertension. J. Am. Heart Assoc. 2012, 1:e001081.